TCGA-A2-A0EV-01A-11R-A034-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 32
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.490
- PROTEIN_SECRETION+0.440
- INTERFERON_GAMMA_RESPONSE+0.370
- ESTROGEN_RESPONSE_EARLY+0.360
- APOPTOSIS+0.350
- COMPLEMENT+0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.310
- PI3K_AKT_MTOR_SIGNALING+0.290
- ESTROGEN_RESPONSE_LATE+0.280
- P53_PATHWAY+0.280
Top 10 suppressed
- MYC_TARGETS_V2-0.480
- KRAS_SIGNALING_DN-0.240
- OXIDATIVE_PHOSPHORYLATION-0.180
- MYC_TARGETS_V1-0.160
- NOTCH_SIGNALING-0.140
- MYOGENESIS-0.110
- WNT_BETA_CATENIN_SIGNALING-0.100
- E2F_TARGETS-0.090
- HYPOXIA-0.090
- GLYCOLYSIS-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-44-6145-01A-11R-1755-07 | — | cohortA1 | 0.833 |
| 2 | SRR8518261 | — | C | 0.825 |
| 3 | SRR26320072 | — | — | 0.801 |
| 4 | SRR934980 | — | — | 0.785 |
| 5 | MNG19 | — | — | 0.783 |
| 6 | TCGA-50-5941-01A-11R-1755-07 | — | cohortA1 | 0.783 |
| 7 | BS_014EVM2D | low-grade glioma | — | 0.781 |
| 8 | TCGA-44-6779-01A-11R-1858-07 | — | cohortA1 | 0.779 |
| 9 | TCGA-EW-A1PE-01A-11R-A144-07 | — | B | 0.779 |
| 10 | BS_0SCXXM6N | low-grade glioma | — | 0.771 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.440 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.360 | Inavolisib | — uncovered |
| APOPTOSIS | 0.350 | Idelalisib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.310 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.290 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.280 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.280 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| PEROXISOME | 0.260 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.250 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.250 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.250 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| COAGULATION | 0.210 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.190 | Inavolisib | — uncovered |